Omalizumab Enhances Sleep and Health status in Chronic rhinosinusitis with nasal polyps

Patients with CRSwNP commonly experience sleep impairment, affecting their quality of life. This study investigates the impact of omalizumab, a therapeutic option, on sleep and health status. Understanding these broader effects is crucial for providing comprehensive care to individuals with this chronic condition.

The study conducted a prespecified exploratory analysis using data from the POLYP 1 and POLYP 2 phase 3 clinical trials and the open-label extension. Sleep outcomes were assessed through the Sino-Nasal Outcome Test-22 (SNOT-22) sleep domain and the Medical Outcomes Study Sleep Scale (MOS-Sleep). Health status was evaluated using the Healthy Days Core Module (HDCM) and sinonasal-specific Patient Global Impression of Change (PGIC).

The key findings of the study were:

• Omalizumab demonstrated significant improvements in sleep characteristics, as measured by the SNOT-22 sleep domain.

• At week 24, patients on omalizumab showed a notable 64% reduction in sleep scores (SNOT-22) compared to those on placebo.

• Improvements were observed across all eight items of the SNOT-22 sleep domain and six of eight sleep outcomes on the MOS-Sleep scale.

• Concurrent enhancements were noted in HDCM, with a 29% improvement, and PGIC, indicating a positive impact on overall health status.

Omalizumab emerges as a promising treatment option not only for reducing sinonasal symptoms but also for improving sleep and overall health status in patients with CRSwNP. These findings underscore the potential holistic benefits of omalizumab, offering valuable insights for comprehensive patient care.

Reference: